Danaher raises dividend to $0.32, up 18.5% from prior

WASHINGTON - Danaher Corporation (NYSE:DHR), a global life sciences and diagnostics company with a market capitalization of $149.6 billion, has declared an 18.5% increase in its regular quarterly cash dividend. The dividend, which has risen from $0.27 to $0.32 per share of its common stock, is scheduled for payment on April 25, 2025, to shareholders of record as of March 28, 2025. According to InvestingPro analysis, the stock is currently trading near its 52-week low of $196.80.

The announcement reflects the company’s commitment to providing value to its shareholders and confidence in its financial strength. InvestingPro data shows that Danaher has maintained dividend payments for 32 consecutive years and has raised its dividend for 7 consecutive years straight. Danaher, known for its focus on scientific innovation and advanced technology, operates in the healthcare sector, partnering with customers to address critical health challenges.

Danaher’s business strategy emphasizes scientific excellence and continuous improvement, aiming to enhance the quality of life and foster sustainable practices for the future. The company employs approximately 63,000 people worldwide, engaging in the development and delivery of life-changing therapies and more accurate diagnostic tools.

This dividend increase is part of Danaher’s ongoing efforts to share its financial success with its investors. The company’s ability to consistently pay and raise dividends is supported by strong fundamentals, including $7.2 billion in EBITDA and $5.3 billion in free cash flow for the last twelve months. Get access to 15+ additional exclusive InvestingPro Tips and comprehensive financial analysis in our Pro Research Report, available with an InvestingPro subscription.

Investors may view this move as a testament to Danaher’s operational efficiency and its ability to generate ample cash flow to support such increases in shareholder returns. The current dividend yield stands at 0.53%, with the company maintaining strong cash flows that sufficiently cover interest payments. As the company continues to navigate the complexities of the global health sector, it remains committed to leveraging science and technology to make a meaningful impact on human health.

The information regarding the dividend increase is based on a press release statement from Danaher Corporation.

In other recent news, Danaher Corporation reported its fourth-quarter 2024 earnings, highlighting a slight miss in earnings per share (EPS) but a notable revenue beat. The company posted an EPS of $2.14, just below the forecasted $2.15, while revenue reached $6.54 billion, surpassing expectations of $6.39 billion. This revenue outperformance was driven by strong performance in the diagnostics and life sciences segments. Analysts from firms such as Nephron Research and Bank of America have been closely monitoring Danaher’s strategic initiatives and revenue trends, reflecting investor optimism despite minor EPS discrepancies.

Danaher’s full-year sales for 2024 stood at $23.9 billion, with a 1% core revenue growth in the fourth quarter. The company’s gross profit margin for the quarter was 59.5%, and it generated $5.3 billion in free cash flow for the year. Looking ahead, Danaher projects a 3% core revenue growth for 2025, despite expecting a 2% revenue headwind due to a stronger U.S. dollar. The company remains focused on innovation and strategic acquisitions, which are seen as key drivers for its long-term growth strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.